Molecular immune responses to aerosol challenge with Francisella tularensis in mice inoculated with live vaccine candidates of varying efficacy

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Shen, Hua ^a   Harris, Gregory ^a   Chen, Wangxue ^a   Sjostedt, Anders ^b   Ryden, Patrik ^b   Conlan, Wayne ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; FRANCISELLA TULARENSIS LIVE VACCINE; FRANCISELLA TULARENSIS SCHU S4 DELETION MUTANT CLPB VACCINE; FRANCISELLA TULARENSIS SCHU S4 DELETION MUTANT FUPA CAPB VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 9; LIVE VACCINE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VACCINE; VASCULOTROPIN; CHEMOKINE; CYTOKINE;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL VIRULENCE; CONTROLLED STUDY; DELETION MUTANT; DOSE RESPONSE; DRUG EFFICACY; DRUG SCREENING; FEMALE; FRANCISELLA TULARENSIS; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOMODULATION; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; LUNG INFECTION; LYMPHATIC SYSTEM INFECTION; MOUSE; NONHUMAN; TULAREMIA; ANIMAL; BAGG ALBINO MOUSE; IMMUNOLOGY; LUNG; LUNG DISEASE; METABOLISM; PATHOLOGY;

BACTERIA (MICROORGANISMS); FRANCISELLA TULARENSIS; MUS;

AEROSOLS; ANIMALS; BACTERIAL VACCINES; CHEMOKINES; CYTOKINES; FRANCISELLA TULARENSIS; LUNG; LUNG DISEASES; MICE; MICE, INBRED BALB C; TULAREMIA;

EID: 78149434685     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013349     Document Type: Article

References (40)

1. Sjostedt A (2007) Tularemia: history, epidemiology, pathogen physiology, and clinical manifestations. Ann N Y Acad Sci 1105: 1-29.
2. Saslaw S, Eigelsbach HT, Prior JA, Wilson HE, Carhart S (1961) Tularemia vaccine study. II. Respiratory challenge. Arch Intern Med 107: 702-714.
3. Hornick RB, Eigelsbach HT (1966) Aerogenic immunization of man with live Tularemia vaccine. Bacteriol Rev 30: 532-538.
4. McCrumb FR (1961) Aerosol Infection of Man with Pasteurella Tularensis. Bacteriol Rev 25: 262-267.
5. Saslaw S, Carhart S (1961) Studies with tularemia vaccines in volunteers. III. Serologic aspects following intracutaneous or respiratory challenge in both vaccinated and nonvaccinated volunteers. Am J Med Sci 241: 689-699.
6. Rick Lyons C, Wu TH (2007) Animal models of Francisella tularensis infection. Ann N Y Acad Sci 1105: 238-265.
7. Conlan JW, Shen H, Kuolee R, Zhao X, Chen W (2005) Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an alphabeta T cell- and interferon gamma- dependent mechanism. Vaccine 23: 2477-2485.
8. Wu TH, Hutt JA, Garrison KA, Berliba LS, Zhou Y, et al. (2005) Intranasal vaccination induces protective immunity against intranasal infection with virulent Francisella tularensis biovar A. Infect Immun 73: 2644-2654.
9. Bakshi CS, Malik M, Mahawar M, Kirimanjeswara GS, Hazlett KR, et al. (2008) An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain. Vaccine 26: 5276-5288.
10. Karttunen R, Andersson G, Ekre HP, Juutinen K, Surcel HM, et al. (1987) Interleukin 2 and gamma interferon production, interleukin 2 receptor expression, and DNA synthesis induced by tularemia antigen in vitro after natural infection or vaccination. J Clin Microbiol 25: 1074-1078.
11. Tarnvik A (1989) Nature of protective immunity to Francisella tularensis. Rev Infect Dis 11: 440-451.
12. Sjostedt A, Eriksson M, Sandstrom G, Tarnvik A (1992) Various membrane proteins of Francisella tularensis induce interferon-gamma production in both CD4+ and CD8+ T cells of primed humans. Immunology 76: 584-592.
13. Ericsson M, Sandstrom G, Sjostedt A, Tarnvik A (1994) Persistence of cellmediated immunity and decline of humoral immunity to the intracellular bacterium Francisella tularensis 25 years after natural infection. J Infect Dis 170: 110-114.
14. McMurry JA, Gregory SH, Moise L, Rivera D, Buus S, et al. (2007) Diversity ofFrancisella tularensis Schu4 antigens recognized by T lymphocytes after naturalinfections in humans: identification of candidate epitopes for inclusion ina rationally designed tularemia vaccine. Vaccine 25: 3179-3191.
15. Salerno-Goncalves R, Hepburn MJ, Bavari S, Sztein MB (2009) Generation of heterogeneous memory T cells by live attenuated tularemia vaccine in humans. Vaccine 28: 195-206.
16. Fuller CL, Brittingham KC, Hepburn MJ, Martin JW, Petitt PL, et al. (2006) Dominance of human innate immune responses in primary Francisella tularensis live vaccine strain vaccination. J Allergy Clin Immunol 117: 1186-1188.
17. Fuller CL, Brittingham KC, Porter MW, Hepburn MJ, Petitt PL, et al. (2007) Transcriptome analysis of human immune responses following live vaccine strain (LVS) Francisella tularensis vaccination. Mol Immunol 44: 3173-3184.
18. Chen W, Shen H, Webb A, KuoLee R, Conlan JW (2003) Tularemia in BALB/ c and C57BL/6 mice vaccinated with Francisella tularensis LVS and challenged intradermally, or by aerosol with virulent isolates of the pathogen: protection varies depending on pathogen virulence, route of exposure, and host genetic background. Vaccine 21: 3690-3700.
19. Green M, Choules G, Rogers D, Titball RW (2005) Efficacy of the live attenuated Francisella tularensis vaccine (LVS) in a murine model of disease. Vaccine 23: 2680-2686.
20. Elkins KL, Cowley SC, Bosio CM (2007) Innate and adaptive immunity to Francisella. Ann N Y Acad Sci 1105: 284-324.
21. Conlan JW, Shen H, Golovliov I, Zingmark C, Oyston PC, et al. (2010) Differential ability of novel attenuated targeted deletion mutants of Francisella tularensis subspecies tularensis strain SCHU S4 to protect mice against aerosol challenge with virulent bacteria: effects of host background and route of immunization. Vaccine 28: 1824-1831.
22. Conlan JW, Zhao X, Harris G, Shen H, Bolanowski M, et al. (2008) Molecular immunology of experimental primary tularemia in mice infected by respiratory or intradermal routes with type A Francisella tularensis. Mol Immunol 45: 2962-2969.
23. Wu TH, Zsemlye JL, Statom GL, Hutt JA, Schrader RM, et al. (2009) Vaccination of Fischer 344 rats against pulmonary infections by Francisella tularensis type A strains. Vaccine 27: 4684-4693.
24. Cowley SC, Meierovics AI, Frelinger JA, Iwakura Y, Elkins KL (2010) Lung CD4- CD8- double-negative T cells are prominent producers of IL-17A and IFN-gamma during primary respiratory murine infection with Francisella tularensis live vaccine strain. J Immunol 184: 5791-5801.
25. Lin Y, Ritchea S, Logar A, Slight S, Messmer M, et al. (2009) Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis. Immunity 31: 799-810.
26. Bosio CM, Bielefeldt-Ohmann H, Belisle JT (2007) Active suppression of the pulmonary immune response by Francisella tularensis Schu4. J Immunol 178: 4538-4547.
27. Markel G, Bar-Haim E, Zahavy E, Cohen H, Cohen O, et al. (2010) The involvement of IL-17A in the murine response to sub-lethal inhalational infection with Francisella tularensis. PLoS One 5: e11176.
28. Woolard MD, Hensley LL, Kawula TH, Frelinger JA (2008) Respiratory Francisella tularensis live vaccine strain infection induces Th17 cells and prostaglandin E2, which inhibits generation of gamma interferon-positive T cells. Infect Immun 76: 2651-2659.
29. Sjostedt A, North RJ, Conlan JW (1996) The requirement of tumour necrosis factor-alpha and interferon-gamma for the expression of protective immunity to secondary murine tularaemia depends on the size of the challenge inoculum. Microbiology 142(Pt 6): 1369-1374.
30. Sjostedt A, Conlan JW, North RJ (1994) Neutrophils are critical for host defense against primary infection with the facultative intracellular bacterium Francisella tularensis in mice and participate in defense against reinfection. Infect Immun 62: 2779-2783.
31. Chen W, KuoLee R, Shen H, Conlan JW (2004) Susceptibility of immunodeficient mice to aerosol and systemic infection with virulent strains of Francisella tularensis. Microb Pathog 36: 311-318.
32. Zhang X, Gao L, Lei L, Zhong Y, Dube P, et al. (2009) A MyD88-dependent early IL-17 production protects mice against airway infection with the obligate intracellular pathogen Chlamydia muridarum. J Immunol 183: 1291-1300.
33. Schulz SM, Kohler G, Holscher C, Iwakura Y, Alber G (2008) IL-17A is produced by Th17, gammadelta T cells and other CD4- lymphocytes during infection with Salmonella enterica serovar Enteritidis and has a mild effect in bacterial clearance. Int Immunol 20: 1129-1138.
34. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, et al. (2007) IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 8: 369-377.
35. Peck A, Mellins ED (2010) Precarious Balance: Th17 Cells in Host Defense. Infect Immun 78: 32-38.
36. Paranavitana C, Zelazowska E, Dasilva L, Pittman PR, Nikolich M (2010) Th17 cytokines in recall responses against Francisella tularensis in humans. J Interferon Cytokine Res 30: 471-476.
37. Higgins SC, Jarnicki AG, Lavelle EC, Mills KH (2006) TLR4 mediates vaccineinduced protective cellular immunity to Bordetella pertussis: role of IL-17- producing T cells. J Immunol 177: 7980-7989.
38. Velin D, Favre L, Bernasconi E, Bachmann D, Pythoud C, et al. (2009) Interleukin-17 is a critical mediator of vaccine-induced reduction of Helicobacter infection in the mouse model. Gastroenterology 136: 2237-2246 e2231.
39. Shibata K, Yamada H, Hara H, Kishihara K, Yoshikai Y (2007) Resident Vdelta1+ gammadelta T cells control early infiltration of neutrophils after Escherichia coli infection via IL-17 production. J Immunol 178: 4466-4472.
40. Kelchtermans H, Schurgers E, Geboes L, Mitera T, Van Damme J, et al. (2009) Effector mechanisms of interleukin-17 in collagen-induced arthritis in the absence of interferon-gamma and counteraction by interferon-gamma. Arthritis Res Ther 11: R122.